Citigroup Issues Positive Forecast for Syndax Pharmaceuticals (NASDAQ:SNDX) Stock Price

Syndax Pharmaceuticals (NASDAQ:SNDX) had its price target boosted by Citigroup from $37.00 to $45.00 in a research report released on Tuesday morning,Benzinga reports. The brokerage currently has a buy rating on the stock.

SNDX has been the topic of a number of other reports. Stifel Nicolaus boosted their target price on shares of Syndax Pharmaceuticals from $40.00 to $41.00 and gave the stock a “buy” rating in a research report on Monday, October 14th. Barclays raised their target price on Syndax Pharmaceuticals from $32.00 to $33.00 and gave the company an “overweight” rating in a research note on Thursday, August 15th. UBS Group assumed coverage on Syndax Pharmaceuticals in a research note on Thursday, October 24th. They issued a “buy” rating and a $37.00 price target on the stock. StockNews.com upgraded Syndax Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, November 15th. Finally, The Goldman Sachs Group upped their target price on Syndax Pharmaceuticals from $30.00 to $33.00 and gave the company a “buy” rating in a research report on Thursday, November 7th. Two investment analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $37.18.

Syndax Pharmaceuticals Trading Down 2.1 %

Shares of Syndax Pharmaceuticals stock opened at $15.77 on Tuesday. Syndax Pharmaceuticals has a twelve month low of $14.97 and a twelve month high of $25.34. The stock has a market cap of $1.35 billion, a price-to-earnings ratio of -4.34 and a beta of 0.92. The company has a fifty day moving average price of $18.82 and a 200 day moving average price of $20.15.

Syndax Pharmaceuticals (NASDAQ:SNDX) last posted its earnings results on Tuesday, November 5th. The company reported ($0.98) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.13) by $0.15. The company had revenue of $12.50 million during the quarter, compared to analyst estimates of $9.16 million. During the same quarter last year, the business posted ($0.73) EPS. Analysts forecast that Syndax Pharmaceuticals will post -3.61 earnings per share for the current year.

Institutional Trading of Syndax Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the business. Northwestern Mutual Wealth Management Co. acquired a new position in shares of Syndax Pharmaceuticals in the 2nd quarter valued at about $27,000. Values First Advisors Inc. acquired a new position in Syndax Pharmaceuticals in the third quarter valued at approximately $30,000. nVerses Capital LLC bought a new position in shares of Syndax Pharmaceuticals during the second quarter valued at approximately $33,000. Quantbot Technologies LP acquired a new stake in shares of Syndax Pharmaceuticals during the 3rd quarter worth approximately $49,000. Finally, Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Syndax Pharmaceuticals by 21.3% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,078 shares of the company’s stock worth $58,000 after purchasing an additional 541 shares during the last quarter.

Syndax Pharmaceuticals Company Profile

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).